Daniel Camus

Daniel Camus has more than 25 years of experience as a senior executive, implementing long-term expansion in complex financial operations, including a recent position as Group Executive Director of Electricité de France (EDF), where he also oversaw international operations at the largest electric utility company in the world. He is well-known among financial leaders in Europe for his deep knowledge of international finance, his personal integrity and his ability as a top-line manager. He holds a PhD in Finance and Economics from the Sorbonne in Paris.

A graduate of the Institut d’Etudes Politiques de Paris specializing in finance, Mr. Camus began his career at Hoechst, a leading company of the chemical industry in Germany. Initially, he covered the financing of all affiliates of the Hoechst Group in Africa. Excelling in strategic planning and development, he was later sent to Montreal to realize the integration of a major acquisition in North America.

Over two decades, Mr. Camus developed and honed his expertise in solving complex financial challenges and steering global transformation through mergers in the health care industry. He first returned to France to join Roussel Uclaf, a pharmaceutical company, where he was soon promoted to Chief Financial Officer. He orchestrated a complex financial restructuring of Roussel in 1997, and re-built the company’s financial control system, becoming General Manager in the process.

Mr. Camus was promoted to head Finance for the pharmaceutical company of Hoechst, the only Frenchman in senior management ranks of a German company. As CFO of Aventis Pharma, following the merger of Hoechst and Rhone-Poulenc, he led the financial structuring of pharmaceutical divisions across more than 130 affiliates.

In 2002, he became Group CFO of Electricité de France, one of the largest energy companies in the world, again leading the transformation of the company in a newly competitive environment and in its stock exchange listing.

In August 2012, Mr. Camus was appointed Chief Financial Officer of The Global Fund to Fight AIDS, Tuberculosis and Malaria. His Board memberships include Cameco Corporation, Saskatoon; Morphosys AG, Munich; SGL Carbon AG, Wiesbaden; Valeo SA, Paris; and Vivendi SA, Paris.